Published in Mol Med on June 01, 1998
Estrogen modulates cutaneous wound healing by downregulating macrophage migration inhibitory factor. J Clin Invest (2003) 1.77
Anti-inflammatory and renal protective actions of stanniocalcin-1 in a model of anti-glomerular basement membrane glomerulonephritis. Am J Pathol (2009) 1.35
Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium. Proc Natl Acad Sci U S A (2002) 1.18
Mammalian stanniocalcin-1 activates mitochondrial antioxidant pathways: new paradigms for regulation of macrophages and endothelium. Am J Physiol Renal Physiol (2009) 1.12
Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERK MAP kinase phosphorylation. Clin Exp Immunol (2008) 1.05
Macrophage migration inhibitory factor (MIF): a key player in protozoan infections. Int J Biol Sci (2011) 0.99
Lupus nephritis: current update. Arthritis Res Ther (2011) 0.97
Up-regulation of macrophage migration inhibitory factor in acute renal allograft rejection in the rat. Clin Exp Immunol (1999) 0.84
Dendritic cells and macrophages in kidney disease. Clin Exp Nephrol (2009) 0.84
Association of the macrophage migration inhibitory factor -173*C allele with childhood nephrotic syndrome. Pediatr Nephrol (2008) 0.81
Macrophage Migration Inhibitory Factor Mediates Proliferative GN via CD74. J Am Soc Nephrol (2015) 0.76
Macrophage Migration Inhibitory Factor in Clinical Kidney Disease. Front Immunol (2016) 0.76
Severe Nephrotoxic Nephritis following Conditional and Kidney-Specific Knockdown of Stanniocalcin-1. PLoS One (2015) 0.75
Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science (1966) 13.12
Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A (1966) 12.29
The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology (1985) 7.77
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (1993) 5.60
The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med (1994) 5.55
MIF as a glucocorticoid-induced modulator of cytokine production. Nature (1995) 5.21
An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A (1996) 3.79
Purification with monoclonal antibody of a predominant leukocyte-common antigen and glycoprotein from rat thymocytes. Eur J Immunol (1979) 3.69
A monoclonal antibody to a constant determinant of the rat T cell antigen receptor that induces T cell activation. Differential reactivity with subsets of immature and mature T lymphocytes. J Exp Med (1989) 2.85
Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids. J Exp Med (1989) 2.32
Rat macrophage lysosomal membrane antigen recognized by monoclonal antibody ED1. Immunology (1994) 2.32
Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol (1997) 2.00
An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med (1996) 1.99
The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med (1997) 1.86
Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med (1995) 1.55
Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest (1988) 1.48
De Novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. Am J Pathol (1996) 1.40
Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit Rev Immunol (1997) 1.37
Initiation and evolution of interstitial leukocytic infiltration in experimental glomerulonephritis. Kidney Int (1991) 1.35
Cloning and characterization of the gene for mouse macrophage migration inhibitory factor (MIF). J Immunol (1995) 1.35
The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int (1989) 1.28
Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist. Kidney Int (1993) 1.22
The interstitial response to renal injury: fibroblast-like cells show phenotypic changes and have reduced potential for erythropoietin gene expression. Kidney Int (1997) 1.15
Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti-GBM Ab GN. Kidney Int (1996) 1.10
A functional role for osteopontin in experimental crescentic glomerulonephritis in the rat. Proc Assoc Am Physicians (1998) 1.08
Mechanism of action of interleukin-2 receptor (IL-2R) monoclonal antibody (MAb) therapy: target cell depletion or inhibition of function? Transplant Proc (1989) 1.07
Local macrophage proliferation in the progression of glomerular and tubulointerstitial injury in rat anti-GBM glomerulonephritis. Kidney Int (1995) 1.01
Interleukin-1 receptor antagonist ameliorates experimental anti-glomerular basement membrane antibody-associated glomerulonephritis. J Clin Invest (1994) 0.97
TNF-alpha up-regulates renal MIF expression in rat crescentic glomerulonephritis. Mol Med (1997) 0.90
Suppression of experimental glomerulonephritis by the interleukin-1 receptor antagonist: inhibition of intercellular adhesion molecule-1 expression. J Am Soc Nephrol (1994) 0.86
Domains of rat interleukin 1 beta involved in type I receptor binding. Endocrinology (1995) 0.86
Suppression of experimental crescentic glomerulonephritis by deoxyspergualin. J Am Soc Nephrol (1993) 0.80
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24
Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol (2001) 7.40
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (1993) 5.60
The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med (1994) 5.55
MIF as a glucocorticoid-induced modulator of cytokine production. Nature (1995) 5.21
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension (2001) 4.41
Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med (2000) 3.89
An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A (1996) 3.79
Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest (1994) 3.70
Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry (1994) 3.58
Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol (1998) 3.09
Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int (1999) 3.09
Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem (1992) 3.06
Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med (1997) 2.98
Early cellular events in a systemic graft-vs.-host reaction. II. Autoradiographic estimates of the frequency of donor lymphocytes which respond to each Ag-B-determined antigenic complex. J Exp Med (1975) 2.78
Alvarado score: an admission criterion in patients with right iliac fossa pain. Surgeon (2003) 2.77
A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem (1995) 2.71
An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature (1996) 2.71
The specific selection of recirculating lymphocytes by antigen in normal and preimmunized rats. J Exp Med (1972) 2.66
Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem (1999) 2.60
Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A (1997) 2.53
Specific unresponsiveness of recirculating lymphocytes ater exposure to histocompatibility antigen in F 1 hybrid rats. Nat New Biol (1971) 2.50
The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proc Natl Acad Sci U S A (1997) 2.36
Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int (1998) 2.35
The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A (2003) 2.29
Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int (2006) 2.22
A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun (2002) 2.21
The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med (1996) 2.21
Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest (2001) 2.20
Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum (1999) 2.17
An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med (1999) 2.10
Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A (1997) 2.10
Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A (1992) 2.09
Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.09
Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene (2007) 2.08
Tissue culture of isolated glomeruli in experimental crescentic glomerulonephritis. J Exp Med (1978) 2.02
Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol (1997) 2.00
An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med (1996) 1.99
Programmed cell death (apoptosis) in human monocytes infected by influenza A virus. Immunobiology (1994) 1.98
Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A (1996) 1.95
Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J (2001) 1.91
The macrophagen in human rapidly progressive glomerulonephritis. Lancet (1976) 1.88
Filarial nematode parasites secrete a homologue of the human cytokine macrophage migration inhibitory factor. Infect Immun (1998) 1.87
Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol (1997) 1.86
The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med (1997) 1.86
Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest (1998) 1.85
Glomerulonephritis. Lancet (2005) 1.81
Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci U S A (2005) 1.79
De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res (2000) 1.78
Epidemiological studies of leukaemia in children and young adults around nuclear facilities: a critical review. Radiat Prot Dosimetry (2008) 1.77
An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. Proc Natl Acad Sci U S A (1999) 1.74
PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int (2001) 1.69
Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene (2006) 1.68
Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia. Kidney Int (2007) 1.66
Elevation of plasma level of macrophage migration inhibitory factor in patients with acute myocardial infarction. Am J Cardiol (2001) 1.65
Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha. J Immunol (1998) 1.63
Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet (1996) 1.63
Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J Clin Invest (1999) 1.62
Misplacement of a right internal jugular vein haemodialysis catheter into the mediastinum. Hong Kong Med J (2004) 1.61
Leukocyte analysis using monoclonal antibodies in human glomerulonephritis. Kidney Int (1987) 1.60
Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Kidney Int (2001) 1.60
The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type II. Evidence for conserved alternative splicing in the 4-phosphatase family. J Biol Chem (1997) 1.60